Genentech, a Member of the Roche Group, today launched an up-to-$800 million partnership with Parvus Therapeutics to develop, manufacture, and commercialize new treatments for inflammatory bowel disease (IBD), autoimmune liver diseases (ALD), and celiac disease (CD) based on Parvus’ Navacim™ precision medicine platform. Navacims are designed to help protect against autoimmune disease by triggering a […]